The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2023 | Incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
Katja Sockel, MD, University Hospital Carl Gustav Carus Dresden, Dresden, Germany, comments on the role of novel immune and targeted agents in the treatment of myelofibrosis (MF), explaining how these may be used before or after allogeneic stem cell transplantation (alloSCT). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
